Sotorasib in KRASG12C mutated lung cancer

被引：0
|
作者：
Olivier, Timothee [1 ]
Prasad, Vinay [2 ]
机构：
[1] Geneva Univ Hosp, Dept Oncol, CH-1205 Geneva, Switzerland
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA
来源：
LANCET | 2024年 / 403卷 / 10422期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] High EGFR Expression Confers Acquired Resistance to Adagrasib - In Vitro Study Using KRASg12C Mutated Lung Cancer Cells
    Hamada, A.
    Suda, K.
    Obata, K.
    Sato, H.
    Oiki, H.
    Fukuda, S.
    Ohara, S.
    Ito, M.
    Soh, J.
    Tsutani, Y.
    Mitsudomi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S315 - S315
  • [32] Oncogenic KRASG12C dependency in colorectal cancer.
    Coker, Oluwadara
    Sorokin, Alexey
    Gale, Kelly
    Gao, Fengqin
    Shen, John Paul
    Kwong, Lawrence
    Wu, Ji
    Lee, Hey Min
    Woods, Melanie
    Villareal, Oscar
    Kopetz, Scott
    CANCER RESEARCH, 2021, 81 (13)
  • [33] Drug Resistance NEWLY SYNTHESIZED KRASG12C MEDIATES ESCAPE FROM KRASG12C INHIBITION
    不详
    CANCER DISCOVERY, 2020, 10 (03) : 341 - 341
  • [34] Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the US
    Zhang, Peng
    Xu, Nong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Characterising the in vivo response of lung tumors to KrasG12C inhibition
    Martins, Carla P.
    Bidar, Abdel
    Karrberg, Lillevi
    Porritt, Michelle
    Seeliger, Frank
    Whiteley, Rebecca
    Hanson, Lyndsey
    Hallengren, Liselotte
    Hardaker, Elizabeth
    Barry, Simon
    Maresca, Maresca
    Bohlooly, Mohammad
    Cosulich, Sabina
    Ross, Sarah
    CANCER RESEARCH, 2020, 80 (16)
  • [36] PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib
    Chan, Chien-Hui
    Chiou, Li-Wen
    Lee, Tsai-Yu
    Liu, Yun-Ru
    Hsieh, Tsung-Han
    Yang, Ching-Yao
    Jeng, Yung-Ming
    BRITISH JOURNAL OF CANCER, 2023, 128 (01) : 148 - 159
  • [37] The combination of neratinib with sotorasib is synergistic in models of HER2-amplified and KRASG12C-mutated cancer
    Castel, Myra E.
    Conlon, Neil T.
    Walsh, Naomi
    Bischof, Georg F.
    Crown, John P.
    Collins, Denis M.
    CANCER RESEARCH, 2024, 84 (06)
  • [38] KRASG12C G12C Inhibitors in Non-Small Cell Lung Cancer: A Review
    Tang, Min
    Wu, Yijun
    Bai, Xiufeng
    Lu, You
    ONCOTARGETS AND THERAPY, 2024, 17 : 683 - 695
  • [39] Validation of an LC-MS/MS method for the determination of sotorasib, a KRASG12C inhibitor, in human plasma
    Wong, Philip
    Akrami, Anna
    Houk, Brett
    Vuu, Irene
    James, Christopher A.
    BIOANALYSIS, 2022, 14 (19) : 1281 - 1292
  • [40] Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation
    Jaenne, Pasi A.
    Riely, Gregory J.
    Gadgeel, Shirish M.
    Heist, Rebecca S.
    Ou, Sai-Hong I.
    Pacheco, Jose M.
    Johnson, Melissa L.
    Sabari, Joshua K.
    Leventakos, Konstantinos
    Yau, Edwin
    Bazhenova, Lyudmila
    Negrao, Marcelo V.
    Pennell, Nathan A.
    Zhang, Jun
    Anderes, Kenna
    Der-Torossian, Hirak
    Kheoh, Thian
    Velastegui, Karen
    Yan, Xiaohong
    Christensen, James G.
    Chao, Richard C.
    Spira, Alexander I.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (02) : 120 - 131
12345